Special Issue

Tumor Microenvironment, Immunity and Tumor Immune Escape Mechanisms: Emerging Treatment Strategies for Fighting Cancer

Message from the Guest Editor

Evading the immune system is one of the hallmarks of cancer. Tumors represent a complex ecosystem infiltrated by immune cell populations and diverse stromal cell types evolving in a special physicochemical milieu and various stress conditions. Tumors escape anti-tumor immunity through cell-intrinsic routes and the assembly of an immunosuppressive tumor microenvironment (TME). Recent cancer immunotherapies have revolutionized the management of many patients with aggressive cancers. This also reveals the potential of boosting pre-existing immunological features in some patients. Nonetheless, a significant proportion of patients remain refractory or rapidly relapse, and the factors involved in resistant and relapsing diseases are still poorly understood. This Special Issue will focus on novel mechanisms involving the TME, malignant cells and points of crosstalk that might be key determinants in immune escape and immunotherapeutic resistance. It will also highlight novel methods and compounds developed targeting the TME and its metabolism to optimize immunotherapy-based interventions and widen the therapeutic options for patients.

Guest Editor

Dr. Stephane Terry
Gustave Roussy, INSERM UMR1186, Integrative Tumor Immunology, University Paris-Saclay, Villejuif, France

Deadline for manuscript submissions

closed (30 September 2021)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/86492

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).